ArticleThe Malaysian journal of medical sciences : MJMS2026
Hepatitis B Seroprevalence and Associated Factors Among Inpatients from 2014 to 2023: A Single-Centre Retrospective Study in a Malaysian Tertiary Hospital.
Article in The Malaysian journal of medical sciences : MJMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) remains a global health burden, causing significant health problems, including morbidity and mortality. The World Health Organization (WHO) aims to reduce new infections by 90% and deaths by 65% by 2030, with a focus on the Western Pacific and Southeast Asia. In Malaysia, HBV incidence rose from 2.26 per 100,000 in 2010 to 12.65 per 100,000 in 2015, classifying the country as having an intermediate burden with a seroprevalence of 1.5% to 9.8%. The major transmission routes include perinatal transmission, blood exposure, sexual contact, and needle sharing. This study aimed to provide insight into the epidemiology and disease burden of HBV in a large tertiary hospital in Malaysia. Insights from this study will assist in future directions regarding public health strategies to reduce the burden of hepatitis B by 2030. Methods: This study investigated the seroprevalence of hepatitis B infection (HBsAg) among inpatients at Hospital Universiti Sains Malaysia over 10 years from 1 January 2014 to 31 December 2023. This retrospective study included patients who underwent HBsAg screening during ward admission. Subjects were selected based on probability sampling after reviewing the inclusion and exclusion criteria. Descriptive and inferential analyses were performed following data collection. Statistical significance was determined by Results: A total of 308 patients were identified. The overall seroprevalence was 9.1% (95% CI: 0.06, 0.12), with annual rates fluctuating between 6.3% and 10.7%. The highest positivity rate was observed in the 45 to 54 age group (14.3%), whereas the lowest positivity rate was observed in those aged > 64 years (5.0%). Males exhibited a higher positivity rate (11.7%) than females (6.5%). Private employees had the highest positivity rate (28.6%) among the occupational groups. Individuals coinfected with HIV had a strikingly high positivity rate of 62.5%. Our analysis identified needle sharing as a significant risk factor, with an adjusted odds ratio of (OR = 8.87; 95% CI: 1.64, 47.91; Conclusion: Our study provides insights into the local epidemiology, the burden of hepatitis B infection, and the factors that contribute to disease transmission. This study highlights the need for targeted public health interventions to reduce risk behaviours, particularly needle sharing, to control the spread of hepatitis B in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.